

**Supplementary Table 1. Characteristic of included patients stratified by sex**

Characteristic	Male (n = 75)	Female (n = 41)	p value
Age, yr	34.37 ± 15.08	33.44 ± 14.67	0.748
Body weight at time of initiation, kg	60.6 ± 13.1	49.5 ± 8.2	0.000 <sup>a</sup>
IBD type			0.607
Crohn's disease	50 (66.6)	30 (73.17)	
Ulcerative colitis	25 (33.3)	11 (26.8)	
Anti-TNF treatment duration	170.57 ± 92.73	137.80 ± 80.49	0.059
Anti-TNF type			0.171
Infliximab	58 (77.3)	37 (90.2)	
Adalimumab	14 (18.7)	4 (9.8)	
Golimumab	3 (4.0)	0	
Combination therapy	39 (52.0)	16 (39.0)	0.253
Immunomodulator type			0.057
Azathioprine	32 (82.1)	10 (62.5)	
6-Mercaptopurine	7 (17.9)	4 (25.0)	
Methotrexate	0	2 (12.5)	
History of abdominal surgery	7 (9.3)	2 (4.9)	0.621
Steroid exposure	69 (98.6)	41 (100)	1.000
Anti-TNF discontinuation	15 (20.0)	20 (48.8)	0.004 <sup>a</sup>
Loss of response	14 (18.7)	17 (41.5)	
Adverse events	1 (1.3)	3 (7.3)	

Values are presented as mean ± SD or number (%).

IBD, inflammatory bowel disease; TNF, tumor necrosis factor.

<sup>a</sup>p < 0.05.